228 related articles for article (PubMed ID: 28758810)
21. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
Kienle E; Lübben G
Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
[TBL] [Abstract][Full Text] [Related]
23. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer.
Sharifi R; Knoll LD; Smith J; Kramolowsky E
Urology; 1998 Feb; 51(2):271-6. PubMed ID: 9495710
[TBL] [Abstract][Full Text] [Related]
24. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
25. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results.
Jocham D
Urol Int; 1998; 60 Suppl 2():18-24; discussion 35. PubMed ID: 9607554
[TBL] [Abstract][Full Text] [Related]
26. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
[TBL] [Abstract][Full Text] [Related]
28. A case of foreign body granuloma induced by subcutaneous injection of leuprorelin acetate─clinical analysis for 335 cases in our hospital─.
Kawai M; Ikoma N; Yamada A; Ota T; Manabe Y; Kato M; Mabuchi T; Ozawa A; Higure T; Terachi T
Tokai J Exp Clin Med; 2014 Sep; 39(3):106-10. PubMed ID: 25248424
[TBL] [Abstract][Full Text] [Related]
29. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
Fujisaki A; Kondo Y; Goto K; Morita T
Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
[TBL] [Abstract][Full Text] [Related]
30. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
[TBL] [Abstract][Full Text] [Related]
31. [Leuprorelin acetate depot].
Mashimo T
Nihon Rinsho; 2000 Jul; 58 Suppl():191-6. PubMed ID: 11022712
[No Abstract] [Full Text] [Related]
32. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
[TBL] [Abstract][Full Text] [Related]
33. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
Lim CN; Salem AH
Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
[TBL] [Abstract][Full Text] [Related]
34. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
Tunn UW; Gruca D; Bacher P
Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
[TBL] [Abstract][Full Text] [Related]
35. [Investigation of incidence and risk factors of subcutaneous granulomas induced by injection of leuprorelin acetate].
Fukui S; Nakai Y; Matsumoto Y; Kagebayashi Y; Samma S
Hinyokika Kiyo; 2015 Feb; 61(2):55-9. PubMed ID: 25812594
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer.
Mostafa NM; Chwalisz K; Larsen L; Mattia-Goldberg C; Spitz A; Pradhan RS
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):270-5. PubMed ID: 27128832
[TBL] [Abstract][Full Text] [Related]
37. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL; Brogden RN
Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
Braeckman J; Michielsen D
Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
[TBL] [Abstract][Full Text] [Related]
39. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
40. [Direct and indirect costs of luteinising hormone-releasing hormone analogues in the treatment of locally advanced or metastatic prostate cancer in Italy].
Fadda V; Maratea D
Recenti Prog Med; 2015 Dec; 106(12):634-40. PubMed ID: 26780073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
